European radiopharmaceutical companies Nuclidium AG and Actithera A/S have attracted substantial venture capital to progress clinical development efforts. Nuclidium closed a CHF79 million ($99 million) Series B round to advance copper-based diagnostic and therapeutic isotopes and expand manufacturing capabilities globally. Concurrently, Actithera raised $75.5 million in Series A funding to initiate clinical work on fibroblast activation protein-targeted pharmacokinetics, aiming to enhance radiopharmaceutical efficacy and pharmacology. These investments underscore growing interest in radiopharma innovation and manufacturing scale-up.